KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Leases (2023 - 2025)

Castle Biosciences' Capital Leases history spans 3 years, with the latest figure at $339000.0 for Q3 2025.

  • For Q3 2025, Capital Leases rose 17.3% year-over-year to $339000.0; the TTM value through Sep 2025 reached $339000.0, up 17.3%, while the annual FY2024 figure was $311000.0, 1144.0% up from the prior year.
  • Capital Leases for Q3 2025 was $339000.0 at Castle Biosciences, down from $364000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $364000.0 in Q2 2025 and bottomed at $25000.0 in Q4 2023.
  • The 3-year median for Capital Leases is $312000.0 (2024), against an average of $281142.9.
  • The largest annual shift saw Capital Leases skyrocketed 1144.0% in 2024 before it increased 16.67% in 2025.
  • A 3-year view of Capital Leases shows it stood at $25000.0 in 2023, then surged by 1144.0% to $311000.0 in 2024, then rose by 9.0% to $339000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Capital Leases are $339000.0 (Q3 2025), $364000.0 (Q2 2025), and $328000.0 (Q1 2025).